Drug Trial Radar · NCT07024784
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
377
Planned (sponsor's estimate)
Start
Jul 30, 2025
Primary completion
Jan 2028
Study completion Feb 2028
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- Collaborators
- GOG Foundation
- First posted
- Jun 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies in adult participants with gynecologic cancers. IMGN151 is an investigational drug being developed for the treatment of gynecologic cancers. Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. Around 377 participants with gynecologic cancers will be enrolled in the study at approximately 50 sites worldwide. Participants will receive intravenous infusions of IMGN151 as monotherapy or in combination with anti-cancer therapies according to their assigned study arm. In Arm A, participants will receive IMGN151 in combination with carboplatin on Day 1 of each cycle. In Arm B, participants will receive IMGN151 in combination with olaparib, twice a day (BID) on Day 1 of each cycle. In Arm C, participants will receive IMGN151 in combination with bevacizumab on Day 1 of each cycle. In Arm D, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm E, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm F, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. The total study duration will be approximately 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Conditions
- Gynecologic Cancers
- Platinum-Sensitive Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer (PSOC)
Interventions
IMGN151Drug
Intravenous (IV) infusion
CarboplatinDrug
Intravenous (IV) infusion
BevacizumabDrug
Intravenous (IV) infusion
OlaparibDrug
Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: Up to approximately 3 years
- Percentage of Participants with Adverse Events (AE)Time frame: Up to approximately 3 years
Locations
21 sites in 3 countries. Site status is shown where the registry gives one.
Start Los Angeles /ID# 281533
Los Angeles, California · Recruiting
University of Colorado Hospital- Aurora /ID# 278232
Aurora, Colorado · Recruiting
University Of Minnesota /ID# 277850
Minneapolis, Minnesota · Recruiting
Holy Name Medical Center /ID# 279017
Teaneck, New Jersey · Recruiting
SUNY Upstate Medical University - Syracuse /ID# 277305
Syracuse, New York · Recruiting
University of Cincinnati Medical Center. /ID# 278925
Cincinnati, Ohio · Recruiting
University Hospitals Cleveland Medical Center /ID# 279601
Cleveland, Ohio · Recruiting
OU Health - Stephenson Cancer Center /ID# 277656
Oklahoma City, Oklahoma · Recruiting
Providence Portland Medical Center /ID# 277727
Portland, Oregon · Recruiting
Women & Infants Hospital /ID# 277930
Providence, Rhode Island · Recruiting
SCRI Oncology Partners /ID# 279733
Nashville, Tennessee · Recruiting
Texas Oncology-Austin North /ID# 279958
Austin, Texas · Recruiting
Next Virginia /ID# 279684
Fairfax, Virginia · Recruiting
Rambam Health Care Campus- Haifa /ID# 276004
Haifa, Israel · Recruiting
Shaare Zedek Medical Center /ID# 275854
Jerusalem, Israel · Recruiting
Rabin Medical Center /ID# 279142
Petah Tikva, Central District, Israel · Recruiting
The Chaim Sheba Medical Center /ID# 275997
Ramat Gan, Tel Aviv, Israel · Recruiting
Tel Aviv Sourasky Medical Center /ID# 275852
Tel Aviv, Tel Aviv, Israel · Recruiting
Hyogo Cancer Center /ID# 276940
Akashi-shi, Hyōgo, Japan · Recruiting
National Cancer Center Hospital /ID# 276715
Chuo-Ku, Tokyo, Japan · Recruiting
The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 276711
Koto-ku, Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.